Kerri Fitzgerald

DocwireNews

<div class="td-post-header"><div class="td-post-sharing-top">
<div id="td_uid_2_5cd4cbdfe0d8f" class="td-post-sharing td-ps-bg td-ps-notext td-post-sharing-style1 ">
<div class="td-post-sharing-visible">
<h2 class="td-social-but-icon">What is an Exclusion Formulary?</h2>
<div></div>
</div>
</div>
</div><div class="td-post-content">
<p>An exclusion formulary places certain medications within a drug class that have clinically supported alternatives in a noncoverage status in an effort to address escalating drug expenditures. On January 1, 2017, four BlueCross BlueShield (BCBS) plans implemented an exclusion formulary consisting of more than 300 excluded drugs. However, there are concerns that this method leads to increased medical resource utilization and costs.</p>
<p>In a study, researchers found that exclusion formularies resulted in significant pharmacy savings and were not associated with increased medical cost or resource utilization. The results of the study were presented at the AMCP Annual Meeting during a poster session titled &ldquo;Exclusion Formulary: Assessment of Medical Costs, Pharmacy Costs, and Resource Utilization Compared to a Concurrent Control Group.&rdquo;</p>
<p>The retrospective cohort study used administrative medical and pharmacy claims. The study included a control group of BCBS members who did not have an exclusion formulary. Included members were required to be continuously enrolled in a fully-insured line of business from January 2016 to December 2017.</p>
<p>Researchers assessed medical and pharmacy costs (defined as annual plan and member expenditures) and medical resource utilization (defined as annual member hospitalizations and emergency room [ER] visits). Researchers conducted a pre- (2016) and post- (2017) difference-in-difference analysis to assess any changes in cost and resource utilization.</p>
<p>To address cost of care, the researchers used a general estimating equation fit with a gamma distribution adjusting for BCBS plan, Charlson Comorbidity Index score, rural-urban setting, age, sex, and zip code&ndash;derived sociodemographic variables.</p>
<p>The final cohort included 116,300 members with an exclusion formulary and 750,446 members without.</p>
<p>During the study period, the exclusion formulary population had significantly lower pharmacy costs (0.2% vs 5.4%;&nbsp;<em>P</em>&lt;0.01) and no increase in medical costs (11.9% vs 12.7%,&nbsp;<em>P</em>=0.69) compared with the control cohort. Incident rate ratios indicated nonsignificant differences for hospitalizations (1.10 vs 1.07;&nbsp;<em>P</em>=0.32) and ER visits (1.03 vs 1.02;&nbsp;<em>P</em>=0.52) between groups.</p>
<p>The researchers noted that for three conditions, exclusion formulary resulted in lower pharmacy costs without a significant difference to medical costs or utilization.</p>
<p>Further research is needed to evaluate the health care impact of these formularies, according to the authors.</p>
</div></div>


Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Exclusion Formulary Results in Pharmacy Savings

Pharmacology

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe